0000921895-23-001766.txt : 20230731 0000921895-23-001766.hdr.sgml : 20230731 20230731193950 ACCESSION NUMBER: 0000921895-23-001766 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230726 FILED AS OF DATE: 20230731 DATE AS OF CHANGE: 20230731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lazar David E. CENTRAL INDEX KEY: 0001932843 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13341 FILM NUMBER: 231129104 MAIL ADDRESS: STREET 1: VILLA 1, 14-43RD STREET STREET 2: JUMEIRAH 2 CITY: DUBAI STATE: C0 ZIP: 00000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000910267 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502444990 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form413531laz_07282023.xml OWNERSHIP DOCUMENT X0508 4 2023-07-26 0 0000910267 TITAN PHARMACEUTICALS INC TTNP 0001932843 Lazar David E. VILLA 1, 14-43RD STREET JUMEIRAH 2 DUBAI C0 00000 UNITED ARAB EMIRATES 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-07-26 4 A 0 100000 0 A 100000 D The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. /s/ David E. Lazar 2023-07-31